Showing 761 - 780 results of 121,857 for search '(( 5 ((026 decrease) OR (a decrease)) ) OR ( a ((fold decrease) OR (mean decrease)) ))', query time: 1.65s Refine Results
  1. 761
  2. 762

    Retigabine and ML213 decrease the constriction tone of human detrusor strips. by Julie Svalø (693320)

    Published 2015
    “…<p>(A) The original DSM tension recordings illustrate the relaxatory effect of retigabine and ML213, which are K<sub>v</sub>7.2–7.5 and K<sub>v</sub>7.2/7.4/7.5 channel activators, respectively. …”
  3. 763
  4. 764
  5. 765

    Decrease in number of activated macrophages in demyelinated nerves subjected to 1hr ES. by Nikki A. McLean (643606)

    Published 2014
    “…Note: ES results in a significant decrease in the ED-1 IF 10d post-LPC (5d post-ES; K) and 12d post-LPC (7d post-ES; N) relative to LPC only in a pattern suggestive of movement toward lateral edges and egress (arrow). …”
  6. 766
  7. 767
  8. 768

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  9. 769
  10. 770
  11. 771

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  12. 772
  13. 773

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  14. 774
  15. 775

    Participants characteristics. by Sakiko Fukui (387048)

    Published 2025
    “…</p><p>Methods</p><p>Sixty-nine deceased older adults from five special nursing homes were studied over 3.5 years (January 2016 to June 2020). …”
  16. 776
  17. 777
  18. 778
  19. 779
  20. 780